Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICARES: Toripalimab Consolidation in ES-SCLC
NCT03971214Phase 1Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jun 2019
- Primary completion
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of toripalimab in small cell lung cancer (SCLC), sponsored by Chinese Academy of Medical Sciences. Primary endpoints: Adverse events at 1 year and Objective remission rate at 24 weeks. Status: unknown.
02
Drugs
toripalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03971214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971214.